There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
BUSINESS
Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
AbbVie saw a dip in its Japan revenue in 2019 in a pullback from the previous year’s spike on the hepatitis C drug Maviret (glecaprevir + pibrentasvir), but its topline still crossed the 100 billion yen mark for the second…
To read the full story
Related Article
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
- AbbVie Japan Set to Join Oncology Fray with CLL Drug, Accelerating FIH Trial Entry
October 9, 2019
- AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
BUSINESS
- Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
- Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
August 19, 2022
- Mochida to Roll Out Once-Daily Epadel on Sept. 12
August 19, 2022
- Forxiga Replaces Januvia as Japan’s No. 1 Diabetes Drug in April-June: IQVIA
August 18, 2022
- Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer
August 18, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…